74 results match your criteria Chemother Res Pract[Journal]


Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Chemother Res Pract 2017 23;2017:8196434. Epub 2017 Oct 23.

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.

Background: It is unknown whether the outcomes of second-line pemetrexed-carboplatin chemotherapy administered after progression on gefitinib are dependent on type of EGFR mutation present at baseline.

Method: Adult non-small-cell lung cancer patients, with exon 19 deletion or exon 21 L858R mutation, who progressed on gefitinib and received pemetrexed-carboplatin chemotherapy were selected for this analysis.

Result: 55 patients received pemetrexed-carboplatin as second-line treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/8196434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672602PMC
October 2017
49 Reads

Interferon-Gamma Improves Macrophages Function against M. tuberculosis in Multidrug-Resistant Tuberculosis Patients.

Chemother Res Pract 2016 12;2016:7295390. Epub 2016 Jul 12.

Department of Microbiology, Kohat University of Science and Technology, KPK, Kohat 26000, Pakistan.

Background. Mycobacterium tuberculosis (M. tuberculosis) that causes tuberculosis (TB) kills millions of infected people annually especially multidrug-resistant tuberculosis (MDR-TB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/7295390DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960331PMC
August 2016
17 Reads

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.

Chemother Res Pract 2016 27;2016:3439707. Epub 2016 Jan 27.

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.

Background. The efficacy, safety, and cost benefit of olanzapine (OLN) when compared to aprepitant (APR) in the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) were evaluated. Methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/3439707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748067PMC
February 2016
46 Reads
5 Citations

Alternative Methods to Treat Nausea and Vomiting from Cancer Chemotherapy.

Chemother Res Pract 2015 8;2015:818759. Epub 2015 Nov 8.

Department of Toxicology, Islamic Azad University, Shahreza Branch and Medical Research Center, Jundishapur Health Development Co., Tehran, Iran.

Chemotherapy Induced Nausea and Vomiting (CINV) is among the most intensive side effects and critical concerns for patients with cancer. Most of these patients experience nausea and vomiting after chemotherapy. Sometimes, this is so annoying that it may prevent them from continuing the therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/818759DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655029PMC
December 2015
10 Reads

Oral Antineoplastic Agents: Assessing the Delay in Care.

Chemother Res Pract 2015 28;2015:512016. Epub 2015 Oct 28.

West Virginia University Healthcare, 1 Medical Center Drive, Morgantown, WV 26506, USA ; Clinical Department, West Virginia University School of Pharmacy, Morgantown, WV 26506, USA.

The study was undertaken to determine the length of time between when a prescription for an oral antineoplastic agent is written by the provider and when the medication is received by the patient and to identify risk factors that significantly increase time to medication receipt. First-time fill prescriptions for oral antineoplastic agents were identified. The date the prescription was written and received by the patient was determined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/512016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641173PMC
November 2015
6 Reads

Using the Promise of Sonodynamic Therapy in the Clinical Setting against Disseminated Cancers.

Chemother Res Pract 2015 25;2015:316015. Epub 2015 Aug 25.

Department of Biology, Syracuse University, 107 College Place, Syracuse, NY 13244, USA.

Sonodynamic therapy (SDT) is a form of ultrasound therapy in which specialized chemotherapeutic agents known as sonosensitizers are administered to increase the efficacy of ultrasound-mediated preferential damage of neoplastic cells. Multiple in vitro and in vivo studies have indicated that SDT has the ability to exhibit profound physical and chemical changes on cellular structure. As supportive as the data have been, assessment of this method at the clinical level has been limited to only solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/316015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562321PMC
September 2015
1 Read

Aloe vera Gel: Effective Therapeutic Agent against Multidrug-Resistant Pseudomonas aeruginosa Isolates Recovered from Burn Wound Infections.

Chemother Res Pract 2015 22;2015:639806. Epub 2015 Jul 22.

Department of Medical Laboratory Sciences, School of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran.

Objective. Aloe vera is an herbal medicinal plant with biological activities, such as antimicrobial, anticancer, anti-inflammatory, and antidiabetic ones, and immunomodulatory properties. The purpose of this study was investigation of in vitro antimicrobial activity of A. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2015/639806/
Publisher Site
http://dx.doi.org/10.1155/2015/639806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525459PMC
August 2015
53 Reads

Postchemotherapy histopathological evaluation of ovarian carcinoma: a 40-case study.

Chemother Res Pract 2015 21;2015:197871. Epub 2015 Jan 21.

Department of Radiotherapy, GGS Medical College, Faridkot 151203, India.

Ovarian carcinomas are conventionally treated with primary debulking surgery followed by chemotherapy. Nowadays neoadjuvant chemotherapy followed by surgery is an upcoming treatment modality for ovarian carcinoma. This study highlights the histopathological changes observed after neoadjuvant chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/197871DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317579PMC
February 2015
14 Reads

Electron microscopy in rat brain slices reveals rapid accumulation of Cisplatin on ribosomes and other cellular components only in glia.

Chemother Res Pract 2014 28;2014:174039. Epub 2014 Dec 28.

Department of Physiology, Universidad Central del Caribe, Bayamón, PR 00960, USA.

Cisplatin is a widely used, effective anticancer drug. Its use, however, is associated with several side effects including nephrotoxicity and neurotoxicity. It is known that cisplatin is accumulated in cells by the organic cation transport system and reacts with nucleotides, damaging them, but the precise target of cisplatin-induced neurotoxicity remains obscure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/174039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291194PMC
January 2015
7 Reads

Protective effect of quercetin on melphalan-induced oxidative stress and impaired renal and hepatic functions in rat.

Chemother Res Pract 2014 11;2014:936526. Epub 2014 Dec 11.

Biochemistry Unit, Department of Chemical Sciences, Ajayi Crowther University, PMB 1066, Oyo, 211213 Oyo State, Nigeria.

One major challenge with the use of anticancer agents is the phenomenon of drug-induced toxicity. Melphalan (MPLN) is an alkylating anticancer agent, while quercetin (QCT) is an antioxidant. We investigated the protective role of quercetin against MPLN-induced toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/936526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276702PMC
January 2015
2 Reads

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients.

Chemother Res Pract 2014 7;2014:856156. Epub 2014 Dec 7.

Department of Medical Oncology, Tata Memorial Hospital, Dr. E. Borges Road, Parel, Mumbai, Maharashtra 400012, India.

Introduction. Brain metastasis is a poor prognostic marker in lung cancer. However it is not known whether amongst patients with EGFR mutation those with brain metastases have a worse outcome. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2014/856156/
Publisher Site
http://dx.doi.org/10.1155/2014/856156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274819PMC
December 2014
53 Reads

Dose-dense epirubicin and cyclophosphamide followed by weekly Paclitaxel in node-positive breast cancer.

Chemother Res Pract 2014 9;2014:259312. Epub 2014 Sep 9.

Department of Radiation & Oncology, Cancer Research Center, Shohadaye-Tajrish Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran.

Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement in node-positive breast cancer patients but the optimal dose schedule has still remained undetermined. Objectives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/259312DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172875PMC
October 2014
39 Reads

Carbapenem Resistance among Enterobacter Species in a Tertiary Care Hospital in Central India.

Chemother Res Pract 2014 10;2014:972646. Epub 2014 Aug 10.

Department of Microbiology, Armed Forces Medical College, Pune 411040, India.

Objective. To detect genes encoding carbapenem resistance among Enterobacter species in a tertiary care hospital in central India. Methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/972646DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142386PMC
September 2014
2 Reads

Imatinib: a breakthrough of targeted therapy in cancer.

Chemother Res Pract 2014 19;2014:357027. Epub 2014 May 19.

Department of Anaesthesia and Intensive Care Unit, Indraprastha Apollo Hospital, New Delhi 110076, India.

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach to management of various cancers and represents a therapeutic breakthrough. Imatinib was one of the first cancer therapies to show the potential for such targeted action. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/357027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055302PMC
June 2014
34 Reads
25 Citations

Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus.

Chemother Res Pract 2014 11;2014:487872. Epub 2014 May 11.

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.

Background. Locally advanced carcinoma of maxillary sinus has been historically reported to have poor prognosis. We evaluated the role of NACT in improving the outcome in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/487872DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037593PMC
June 2014
19 Reads

Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model.

Chemother Res Pract 2014 30;2014:570241. Epub 2014 Apr 30.

Instituto de Química y Fisicoquímica Biológica (UBA-CONICET), Facultad de Farmacia y Bioquímica, University of Buenos Aires, Buenos Aires, Argentina.

Since anthracycline-induced cardiotoxicity (AIC), a complication of anthracycline-based chemotherapies, is thought to involve iron, concerns exist about using iron for anaemia treatment in anthracycline-receiving cancer patients. This study evaluated how intravenous ferric carboxymaltose (FCM) modulates the influence of iron deficiency anaemia (IDA) and doxorubicin (3-5 mg per kg body weight [BW]) on oxidative/nitrosative stress, inflammation, and cardiorenal function in spontaneously hypertensive stroke-prone (SHR-SP) rats. FCM was given as repeated small or single total dose (15 mg iron per kg BW), either concurrent with or three days after doxorubicin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/570241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022115PMC
May 2014
52 Reads

A postauthorization survey to document the therapeutic management of oxaliplatin as a first-line chemotherapy regimen in South Africa in patients with metastatic colorectal cancer.

Chemother Res Pract 2014 10;2014:520701. Epub 2014 Apr 10.

Medical Department, Sanofi South Africa, Midrand 1682, South Africa.

Oxaliplatin is a standard first-line treatment for metastatic colorectal cancer. The objectives were to document the therapeutic management of oxaliplatin in South Africa, determine the incidence and severity of sensory neuropathy, and record the 2-year survival rate. Meccelox was a prospective, noncontrolled, open label, multicentre, observational survey of adult patients with stage IV metastatic colorectal cancer treated with oxaliplatin-based chemotherapeutic regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/520701DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003749PMC
May 2014
17 Reads

Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX.

Chemother Res Pract 2013 29;2013:379870. Epub 2013 Sep 29.

Department of Pharmacology, University of Karachi, Karachi 75270, Pakistan ; Department of Pharmacy, Jinnah University for Women, Karachi 74600, Pakistan ; Ziauddin College of Pharmacy, Ziauddin University, 4/B, Block 6, Shahrah-e-Ghalib, Clifton, Karachi 75600, Pakistan.

The study is designed to assess the frequency and severity of few dose limiting neurological adverse effects of four different schedules of FOLFOX. Patients with histologically confirmed advanced colorectal carcinoma (CRC) were included in the study. Toxicity was graded according to CTC v 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/379870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804288PMC
November 2013
12 Reads

Self-management of oxaliplatin-related peripheral neuropathy in colorectal cancer survivors.

Chemother Res Pract 2013 25;2013:547932. Epub 2013 Aug 25.

University of South Florida College of Nursing in Tampa, FL 33612, USA ; University of Massachusetts Boston, Boston, MA 02125, USA ; Dana Farber Cancer Institute, Boston, MA 02215, USA.

Purpose. The purpose of this study was to evaluate medications that cancer survivors with oxaliplatin-induced peripheral neuropathy take to control neuropathic symptom, and to explore self-management techniques used at home to provide temporary relief of painful neuropathy. This was a mixed methods, descriptive, cross-sectional study using self-reported data from colorectal cancer survivors previously treated with oxaliplatin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/547932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766977PMC
September 2013

Identification of Functional Regulatory Residues of the β -Lactam Inducible Penicillin Binding Protein in Methicillin-Resistant Staphylococcus aureus.

Chemother Res Pract 2013 29;2013:614670. Epub 2013 Jul 29.

Center for Bioinformatics & Computational Biology, Department of Biology, Jackson State University, Jackson, MS 39217, USA.

Resistance to methicillin by Staphylococcus aureus is a persistent clinical problem worldwide. A mechanism for resistance has been proposed in which methicillin resistant Staphylococcus aureus (MRSA) isolates acquired a new protein called β -lactam inducible penicillin binding protein (PBP-2'). The PBP-2' functions by substituting other penicillin binding proteins which have been inhibited by β -lactam antibiotics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/614670DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745919PMC
August 2013
2 Reads

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases.

Chemother Res Pract 2013 13;2013:726925. Epub 2013 May 13.

Department of Dermatology, Anheuser-Busch Institute, Saint Louis University, 1402 S. Grand Boulevard., 4th Floor, St. Louis, MO 63104, USA.

A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University. There were 5 men and 3 women; median age was 52.2 years (26. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/726925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666432PMC
June 2013
12 Reads

Lomustine analogous drug structures for intervention of brain and spinal cord tumors: the benefit of in silico substructure search and analysis.

Authors:
Ronald Bartzatt

Chemother Res Pract 2013 16;2013:360624. Epub 2013 Apr 16.

University of Nebraska, College of Arts & Sciences, Durham Science Center, 6001 Dodge Street, Omaha, NE 68182, USA.

Lomustine is a nitrosourea anticancer agent shown to be effective for treatment of childhood medulloblastoma. In silico substructure searches produced 17 novel nitrosourea agents analogous to lumustine and retaining activity for DNA alkylation and cytotoxic activity. The mean values for Log P, polar surface area, formula weight, number of oxygens & nitrogens, and rotatable bonds were 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/360624DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652141PMC
May 2013
1 Read

Inhibition of NF- κ B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ -Radiation Cytotoxicity in Glioblastoma Cells.

Chemother Res Pract 2013 21;2013:593020. Epub 2013 Feb 21.

Department of Pediatrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil ; Laboratório de Pediatria, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (USP), Bloco G, Avenida Bandeirantes, 3900 Bairro Monte Alegre, 14048-900 Ribeirão Preto, SP, Brazil.

Despite advances in neurosurgery and aggressive treatment with temozolomide (TMZ) and radiation, the overall survival of patients with glioblastoma (GBM) remains poor. Vast evidence has indicated that the nuclear factor NF- κ B is constitutively activated in cancer cells, playing key roles in growth and survival. Recently, Dehydroxymethylepoxyquinomicin (DHMEQ) has shown to be a selective NF- κ B inhibitor with antiproliferative properties in GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/593020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594939PMC

Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review.

Chemother Res Pract 2013 21;2013:386809. Epub 2013 Feb 21.

Department of Urology, Patras University Hospital, 26500 Patras, Greece.

High-risk prostate cancer represents a pretentious clinical problem since a significant number of its patients will relapse and progress after radical prostatectomy. Neoadjuvant chemotherapy may be valuable since its efficacy in hormone-resistant prostate cancer has been established. In this paper, we report studies of neoadjuvant chemotherapies that have been used in high-risk patients prior to radical prostatectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/386809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594907PMC
March 2013
6 Reads

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.

Chemother Res Pract 2012 20;2012:743193. Epub 2012 Dec 20.

Department of Internal Medicine, Emory University, Atlanta, GA 30322, USA.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20-30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/743193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539433PMC
January 2013
1 Read

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors.

Chemother Res Pract 2012 24;2012:291421. Epub 2012 Dec 24.

Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2012/291421/
Publisher Site
http://dx.doi.org/10.1155/2012/291421DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540736PMC
January 2013
8 Reads

Chemotherapy and dietary phytochemical agents.

Authors:
Katrin Sak

Chemother Res Pract 2012 20;2012:282570. Epub 2012 Dec 20.

NGO Praeventio, Näituse 22-3, 50407 Tartu, Estonia.

Chemotherapy has been used for cancer treatment already for almost 70 years by targeting the proliferation potential and metastasising ability of tumour cells. Despite the progress made in the development of potent chemotherapy drugs, their toxicity to normal tissues and adverse side effects in multiple organ systems as well as drug resistance have remained the major obstacles for the successful clinical use. Cytotoxic agents decrease considerably the quality of life of cancer patients manifesting as acute complaints and impacting the life of survivors also for years after the treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/282570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539428PMC
January 2013
21 Reads

Advances in Targeting HER3 as an Anticancer Therapy.

Chemother Res Pract 2012 7;2012:817304. Epub 2012 Nov 7.

State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangdong, Guangzhou 510060, China ; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road, NE, Atlanta, GA 30322, USA.

HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of HER3 in signal transduction and its potential role in acquired resistance to EGFR- and HER2-targeted therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/817304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502787PMC
December 2012
14 Reads

The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck.

Chemother Res Pract 2012 13;2012:761518. Epub 2012 Sep 13.

Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford University, Stanford, CA 94305, USA.

Targeting of the EGF receptor (EGFR) has become a standard of care in several tumor types. In squamous cell carcinoma of the head and neck, monoclonal antibodies directed against EGFR have become a regular component of therapy for curative as well as palliative treatment strategies. These agents have anti-tumor efficacy as a single modality and have demonstrated synergistic tumor killing when combined with radiation and/or chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/761518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488396PMC
November 2012
4 Reads

Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review.

Chemother Res Pract 2012 14;2012:387172. Epub 2012 Oct 14.

Department of Medicine, Montefiore Medical Center, 111 210th Street, Bronx, NY 10467, USA.

Colorectal cancer is the second most common malignancy among men and women in the United States, and the 5-year survival rate remains poor despite recent advances in chemotherapy and targeted agents. The mainstay of therapy for advanced disease remains the cytotoxic chemotherapy including 5-FU, irinotecan, and oxaliplatin. The USFDA approval and introduction of targeted therapies, including cetuximab and panitumumab (monoclonal antibodies targeting the epidermal growth factor receptor (EGFR)) and bevacizumab (monoclonal antibody targeting the vascular epithelial growth factor (VEGF)), has improved the median survival of patients with metastatic colorectal cancer to around 24 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/387172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477664PMC
October 2012
10 Reads

Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.

Chemother Res Pract 2012 8;2012:198197. Epub 2012 Oct 8.

Beth Israel Medical Center, Phillips Ambulatory Care Center, Continuum Cancer Centers of New York, 10 Union Square East, Suite 4C, New York, NY, USA ; Section of Hematology/Oncology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.

Patients with metastatic colorectal cancer have a poor prognosis and present a challenge to clinicians. The role of the antiepidermal growth factor receptor (EGFR) pathway in tumorogenesis and tumor progression has been well defined. This paper will review the use of anti-EGFR monoclonal antibodies in the treatment of operable, as well as metastatic colorectal cancer both in the setting of KRAS mutation unselected patients and later in KRAS wild-type patients. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2012/198197/
Publisher Site
http://dx.doi.org/10.1155/2012/198197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472558PMC
October 2012
5 Reads

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.

Chemother Res Pract 2012 27;2012:901320. Epub 2012 Sep 27.

Aerodigestive and Thoracic Tumor Program, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant disease is present. Many patients with localized disease are treated with chemoradiotherapy, either in the definitive or adjuvant setting, and those with metastatic disease are treated with palliative chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/901320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896PMC
October 2012
12 Reads

Neoadjuvant chemoradiation in squamous cell carcinoma of the maxillary sinus: a 26-year experience.

Chemother Res Pract 2012 29;2012:413589. Epub 2012 Sep 29.

Department of Oral and Cranio-Maxillo and Facial Plastic Surgery, University of Cologne, Kerpener Straße 62, 50931 Cologne, Germany ; Center of Integrated Oncology (CIO) Cologne-Bonn, Kerpener Straße 62, 50931 Cologne, Germany.

Background. The aim of our study was to evaluate the effects of neoadjuvant platinum-based radiochemotherapy (RCT) in patients with maxillary sinus squamous cell carcinoma and to compare the results with other multimodality treatment concepts for advanced-stage maxillary sinus carcinoma in the literature. Methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/413589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465876PMC
October 2012
23 Reads

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.

Chemother Res Pract 2012 11;2012:351210. Epub 2012 Sep 11.

Division of Oncology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New york, NY 10461, USA.

Epidermal growth factor receptor (EGFR) inhibition has now been well established as an effective treatment for various cancers. The EGFR belongs to the ErbB family of tyrosine kinase receptors which regulate tumor cell differentiation, survival and proliferation. Activation of EGFR drives tumorigenesis in lung, head and neck, colorectal and pancreatic cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/351210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446637PMC
September 2012
56 Reads

Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis.

Chemother Res Pract 2012 2;2012:490804. Epub 2012 Sep 2.

School of Medical Sciences, University of Adelaide, North Terrace, Adelaide, SA 5005, Australia.

"Mucositis" is the clinical term used to describe ulceration and damage of the mucous membranes of the entire gastrointestinal tract (GIT) following cytotoxic cancer chemotherapy and radiation therapy common symptoms include abdominal pain, bloating, diarrhoea, vomiting, and constipation resulting in both a significant clinical and financial burden. Chemotherapeutic drugs cause upregulation of stress response genes including NFκB, that in turn upregulate the production of proinflammatory cytokines such as interleukin-1β (IL-1β), Interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α). These proinflammatory cytokines are responsible for initiating inflammation in response to tissue injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/490804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437608PMC
September 2012
11 Reads

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.

Chemother Res Pract 2012 29;2012:817297. Epub 2012 Aug 29.

Division of Hematology/Oncology, Department of Medicine, USCF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.

The epidermal growth factor receptor (EGFR) is a well-characterized oncogene that is frequently activated by somatic kinase domain mutations in non-small cell lung cancer (NSCLC). EGFR TKIs are effective therapies for NSCLC patients whose tumors harbor an EGFR activating mutation. However, EGFR TKI treatment is not curative in patients because of both primary and secondary treatment resistance. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2012/817297/
Publisher Site
http://dx.doi.org/10.1155/2012/817297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437267PMC
September 2012
26 Reads

Induction chemotherapy in locally advanced pharyngolaryngeal cancers with stridor: is it feasible and safe?

Chemother Res Pract 2012 12;2012:549170. Epub 2012 Aug 12.

Department of Medical Oncology, Tata Memorial Hospital, Mumbai 400012, India.

Background. The standard initial management of patients with locally advanced pharyngolaryngeal presenting with stridor is tracheostomy. Tracheostomy has been shown to negatively impact cancer-related outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/549170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424664PMC
September 2012
10 Reads

Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles.

Chemother Res Pract 2012 15;2012:905796. Epub 2012 Jul 15.

Department of Pharmaceutical Sciences and Center for Drug Delivery and Nanomedicine, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-5830, USA.

The therapeutic performance of oxaliplatin can be improved by incorporating the central cis-dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt) motif into the core cross-linked block copolymer micelles. We describe here the preparation, cellular uptake, and in vivo evaluation of core cross-linked micelles loaded with DACHPt. Stable drug-loaded micelles were prepared at high drug loading (~25 w/w%) and displayed a considerably increased in vitro cytotoxicity compared to free oxaliplatin against A2780 ovarian cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/905796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403332PMC
August 2012
20 Reads

Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.

Authors:
Rita Nahta

Chemother Res Pract 2012 9;2012:648965. Epub 2012 Jul 9.

Departments of Pharmacology, Hematology and Medical Oncology, School of Medicine; Winship Cancer Institute; Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA.

Resistance to the HER2-targeted antibody trastuzumab is a major clinical concern in the treatment of HER2-overexpressing metastatic breast cancer. Increased expression or signaling of the insulin-like growth factor-I receptor (IGF-IR) has been reported in a subset of cell lines and clinical samples derived from trastuzumab-resistant breast cancers. Genetic and pharmacologic inhibition of IGF-IR signaling has been shown to improve response to trastuzumab in trastuzumab-naïve and trastuzumab-resistant models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/648965DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399380PMC
August 2012
8 Reads

Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin.

Chemother Res Pract 2012 1;2012:268681. Epub 2012 Jul 1.

UFR Pharmacie, FRE CNRS/URCA no. 3481, Université de Reims Champagne-Ardenne, 51096 Reims, Cedex, France.

Anticancer drug resistance is a multifactorial process that includes acquired and de novo drug resistances. Acquired resistance develops during treatment, while de novo resistance is the primary way for tumor cells to escape chemotherapy. Tumor microenvironment has been recently shown to be one of the important factors contributing to de novo resistance and called environment-mediated drug resistance (EMDR). Read More

View Article

Download full-text PDF

Source
http://downloads.hindawi.com/journals/chrp/2012/268681.pdf
Web Search
http://www.hindawi.com/journals/cherp/2012/268681/
Publisher Site
http://dx.doi.org/10.1155/2012/268681DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395309PMC
August 2012
6 Reads

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer.

Chemother Res Pract 2012 26;2012:359041. Epub 2012 Jun 26.

The Ohio State University Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA.

There have been significant developments in colon cancer research over the last few years, enabling us to better characterize tumors individually and classifying them according to certain molecular or genetic features. Currently, we are able to use KRAS mutational status as a guide to therapy with anti-epidermal growth factor receptor antibodies. Other molecular features under research include BRAF mutation, microsatellite instability, and CpG island methylation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/359041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389642PMC
August 2012
4 Reads

Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy.

Chemother Res Pract 2012 18;2012:319287. Epub 2012 Jun 18.

OncoRay-National Center for Radiation Research in Oncology, Medical Faculty Carl Gustav Carus, Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany.

Cancer resistance to therapy presents an ongoing and unsolved obstacle, which has clear impact on patient's survival. In order to address this problem, novel in vitro models have been established and are currently developed that enable data generation in a more physiological context. For example, extracellular-matrix- (ECM-) based scaffolds lead to the identification of integrins and integrin-associated signaling molecules as key promoters of cancer cell resistance to radio- and chemotherapy as well as modern molecular agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/319287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385588PMC

Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

Chemother Res Pract 2012 14;2012:838509. Epub 2012 May 14.

Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia.

There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of personalized treatment for people with certain tumours. The epidermal growth factor receptor (EGFR) and K-ras are two such targets that can help classify tumours on a molecular basis and guide treatment decisions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/838509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359779PMC
August 2012
2 Reads

Integrin signaling in cancer cell survival and chemoresistance.

Chemother Res Pract 2012 11;2012:283181. Epub 2012 Apr 11.

Pavillon CHUL, Centre de Recherche du CHUQ and Faculté de Médecine, Université Laval, Québec, QC, Canada G1V 4G2.

Resistance to apoptosis and chemotherapy is a hallmark of cancer cells, and it is a critical factor in cancer recurrence and patient relapse. Extracellular matrix (ECM) via its receptors, the integrins, has emerged as a major pathway contributing to cancer cell survival and resistance to chemotherapy. Several studies over the last decade have demonstrated that ECM/integrin signaling provides a survival advantage to various cancer cell types against numerous chemotherapeutic drugs and against antibody therapy. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2012/283181/
Publisher Site
http://dx.doi.org/10.1155/2012/283181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332161PMC
August 2012
7 Reads

Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic Acid.

Chemother Res Pract 2012 10;2012:858590. Epub 2012 Apr 10.

Medical Department III, Ludwig-Maximilians University of Munich, Campus Großhadern, 81377 Munich, Germany.

Purpose. Bone loss is a common phenomenon following allogeneic haematopoietic stem cell transplantation (allo-HSCT). The study aimed on tolerance and efficacy of zoledronic acid (ZA) in patients after allo-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/858590DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328888PMC
August 2012
47 Reads

Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.

Chemother Res Pract 2012 14;2012:913848. Epub 2012 Mar 14.

Analysis Group, Inc., Boston, MA 02199, USA.

Objective. Chemotherapy-associated peripheral neuropathy (CAPN) is a painful side-effect of chemotherapy. This study assesses healthcare and workloss costs of CAPN patients with breast, ovarian, head/neck, or non-small cell lung cancer (NSCLC) from a third-party payor/employer perspective. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2012/913848/
Publisher Site
http://dx.doi.org/10.1155/2012/913848DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312207PMC
August 2012
10 Reads

Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours.

Chemother Res Pract 2012 14;2012:721873. Epub 2012 Feb 14.

INSERM U542 and U602, Paul Brousse Hospital, Paris XI University, 16 Avenue. PV Couturier, 94807 Villejuif, France.

The aim of this study was to establish the criteria for methodology of cellular "anti-IGF-I" therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell "vaccines" should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/721873DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287029PMC
August 2012
13 Reads

β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells.

Chemother Res Pract 2012 12;2012:192362. Epub 2012 Feb 12.

Departments of Basic Medical Sciences and Experimental Medicine, IRBLleida University of Lleida, 25198 Lleida, Spain.

Glioblastoma multiforme (GBM) is a commonly occurring brain tumor with a poor prognosis. GBM can develop both "de novo" or evolve from a previous astrocytoma and is characterized by high proliferation and infiltration into the surrounding tissue. Following treatment (surgery, radiotherapy, and chemotherapy), tumors often reappear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/192362DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286890PMC
August 2012
7 Reads

Susceptibility of bifidobacteria of animal origin to selected antimicrobial agents.

Chemother Res Pract 2011 5;2011:989520. Epub 2011 Apr 5.

Department of Food Sciences and Technology, Institute of Food Sciences, BOKU-University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria.

Strains of the genus Bifidobacterium are frequently used as probiotics, for which the absence of acquired antimicrobial resistance has become an important safety criterion. This clarifies the need for antibiotic susceptibility data for bifidobacteria. Based on a recently published standard for antimicrobial susceptibility testing of bifidobacteria with broth microdilution method, the range of susceptibility to selected antibiotics in 117 animal bifidobacterial strains was examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2011/989520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265246PMC
August 2012
11 Reads

Nedaplatin: a radiosensitizing agent for patients with cervical cancer.

Chemother Res Pract 2011 21;2011:963159. Epub 2010 Sep 21.

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Despite the recent advances in the management of cervical cancer using cisplatin-based concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary. Nedaplatin (cis-diammine-glycoplatinum), a derivative of cisplatin, was developed with the aim of producing a treatment with a similar effectiveness to cisplatin but decreased renal and gastrointestinal toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2011/963159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265244PMC
August 2012
3 Reads